Montaner JS - Search Results

1

Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996.

Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, O'Shaughnessy MV, Hogg RS. Wood E, et al. Among authors: montaner js. AIDS. 2002 Oct 18;16(15):2065-72. doi: 10.1097/00002030-200210180-00012. AIDS. 2002. PMID: 12370506

2

The T cell receptor V beta repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infection.

Grant M, Pardoe I, Whaley M, Montaner JS, Harrigan PR. Grant M, et al. Among authors: montaner js. AIDS. 2002 Jan 25;16(2):287-90. doi: 10.1097/00002030-200201250-00019. AIDS. 2002. PMID: 11807314

3

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS. Côté HC, et al. Among authors: montaner js. N Engl J Med. 2002 Mar 14;346(11):811-20. doi: 10.1056/NEJMoa012035. N Engl J Med. 2002. PMID: 11893792 Free article.

4

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.

Wood E, Tyndall MW, Spittal PM, Li K, Hogg RS, Montaner JS, O'Shaughnessy MV, Schechter MT. Wood E, et al. Among authors: montaner js. AIDS. 2002 Apr 12;16(6):941-3. doi: 10.1097/00002030-200204120-00021. AIDS. 2002. PMID: 11919503

5

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.

Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS. Hogg RS, et al. Among authors: montaner js. AIDS. 2002 May 3;16(7):1051-8. doi: 10.1097/00002030-200205030-00012. AIDS. 2002. PMID: 11953472

6

Prescribing practices in a population-based HIV postexposure prophylaxis program.

Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O'Shaughnessy MV, Hogg RS. Braitstein P, et al. Among authors: montaner js. AIDS. 2002 May 3;16(7):1067-70. doi: 10.1097/00002030-200205030-00014. AIDS. 2002. PMID: 11953474

7

To stop or not to stop: that is the question, but what is the answer?

Hogg RS, Havlir D, Miller V, Montaner JS. Hogg RS, et al. Among authors: montaner js. AIDS. 2002 Mar 29;16(5):787-9. doi: 10.1097/00002030-200203290-00015. AIDS. 2002. PMID: 11964536 No abstract available.

8

Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.

Harris M, Alexander C, O'Shaughnessy M, Montaner JS. Harris M, et al. Among authors: montaner js. AIDS. 2002 Mar 29;16(5):798-9. doi: 10.1097/00002030-200203290-00019. AIDS. 2002. PMID: 11964540 No abstract available.

9

Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.

Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O'Shaughnessy MV, Hogg RS. Braitstein P, et al. Among authors: montaner js. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):547-8. doi: 10.1097/00126334-200204150-00019. J Acquir Immune Defic Syndr. 2002. PMID: 11981375 No abstract available.

10

Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.

Alexander CS, Montessori V, Wynhoven B, Dong W, Chan K, O'Shaughnessy MV, Mo T, Piaseczny M, Montaner JS, Harrigan PR. Alexander CS, et al. Among authors: montaner js. Antivir Ther. 2002 Mar;7(1):31-5. Antivir Ther. 2002. PMID: 12008785

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

822 results

Search Page

Filters